
Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first effective treatment of xylazine overdose in people.
April 03, 2024
LA JOLLA, CA Xylazine is an FDA-approved sedative and pain reliever for use in animals, but it has severe adverse effects when used in humans. It is now illicitly being added to opioids, like fentanyl and heroin, as well as cocaine leading to a sharp rise in overdose deaths.
Now, Scripps Research chemical biologists have developed a vaccine to block the effects of xylazine's toxicity. The vaccine works by training the immune system to attack the drug, which is described in a new paper published in Chemical Communications on April 1, 2024.
We demonstrated that a vaccine can reverse the symptoms of a xylazine overdose in rodents, says study senior author Kim D. Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry at Scripps Research. There is currently no remedy for xylazine poisoning other than supportive care, thus, we believe our research efforts and the data we have provided will pave the way for an effective treatment in humans.
The rapid increase in lethal drug overdoses attributed to xylazine combined with fentanyl prompted the White House Office of National Drug Control Policy to declare this combination an emerging threat to the United States. Xylazine intoxication presents similarly to opioid overdose, causing respiratory and central nervous system depression, and it can heighten the effects of opioids. However, naloxone typically administered to reverse the effects of opioids does not tackle the impact of xylazine, highlighting the need for effective measures to treat acute toxicity caused by xylazine.
Researchers suspect xylazine works by reducing blood flow to the brain, among other areas of the body. The drug also causes non-healing skin lesions and wounds, often located on the forearms and lower legs, that can require amputation in some cases giving it the nickname zombie drug.
Although no treatment currently exists, targeted vaccines may offer a solution. Vaccines nudge the immune system to create antibodies to fend off invaders. Antibodies can target viruses, bacteria and toxins. However, sometimes molecules are too small to initiate an immune response, as is the case with xylazine. So, to circumvent this problem, the researchers created a vaccine using a design principle that Janda pioneered, which relies on pairing the drug molecule (called a hapten) with a larger carrier molecule (a protein) and an adjuvant.
In this study, the scientists combined a xylazine hapten with multiple different protein types, to see which combination would create a robust immune response against xylazine. The team tested three vaccine formulations (termed TT, KLH and CRM197, based on the protein involved) to see which vaccine cocktail could help rodents after being challenged with xylazine. One of the three vaccines (TT) significantly increased movement in mice given xylazine after 10 minutes, while two of the three vaccines (TT and KLH) led to an improvement in breathing.
The scientists also examined how these vaccines would limit xylazine blood brain barrier, (BBB) permeation, a filtering mechanism that scrutinizes drug penetration. When xylazine was injected, it immediately crossed into the brain to bind with receptors. Antibodies typically cannot navigate the BBB; however, two of the three vaccines (TT and KLH) showed a strong ability to stop xylazine from reaching its receptors in the brain, limiting its detrimental effects.
A provisional patent has been filed on the research. In the future, his team will build off this work to create a bifunctional antibody that will reverse both fentanyl and xylazine's toxicity simultaneously, something that naloxone cannot do.
A monoclonal antibody treatment could be given in tandem with the vaccine to provide both immediate and long-term protection from both opioid substance use disorders as well as opioid-xylazine overdoses, says Janda. This strategy could make a significant impact on the opioid epidemic.
Evaluation of a Hapten Conjugate Vaccine Against the Zombie Drug' Xylazine was co-authored by Mingliang Lin, Lisa M. Eubanks, Bin Zhou, and Kim D. Janda, all of Scripps Research.
Funding for the study was provided by the Shadek family and Pearson Foundation.
Chemistry Janda, Kim
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
02/05/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
01/05/2026
January 5 2026, 18:30 (PST) NBCUniversal's Peacock to Be First Streamer to ...
20/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Blackmagic Design has announced the ATEM 4 M/E Constellation IP and ATEM 4 M/E Constellation IP Plus, two SMPTE 2110-native live production switchers. The ATEM ...
19/04/2026
Grass Valley is finding the right balance between its hardware heritage with an ...
19/04/2026
Oracle's strategy rests on the foundational strengths of Oracle Cloud Infras...
19/04/2026
Program Productions, the live sports production industry's leading crewer, i...
19/04/2026
At the 2026 NAB Show in Las Vegas, SVG sat down with Joe Scionti, Account Manage...
19/04/2026
At its 2026 NAB Show keynote event, Ross Video came out swinging with one of its...
19/04/2026
Evertz (Booth N817) is set to present new services within its evertz.io platform...
19/04/2026
Evertz (Booth N817) will showcase its IPMX-certified NUCLEUS platform alongside ...
19/04/2026
Evertz (Booth N817) is set to showcase ENX at NAB 2026, a media core platform designed to support hybrid SDI and IP infrastructures in production facilities and...
19/04/2026
Evertz (Booth N817) will introduce Studer VistaVUE Touch at NAB 2026, a control surface designed to integrate audio, video and control workflows within a custom...
19/04/2026
Evertz (Booth N817) will highlight X-CALIBER at NAB 2026, an encoding and decodi...
19/04/2026
Cobalt Digital (Booth N1340) will introduce the blueCORE family of standalone si...
19/04/2026
Chyron and Asport (Booth N2441) will demonstrate an integrated sports video work...
19/04/2026
MediaKind (Booth W1743) provided an update on its Multiview deployments at NAB S...
19/04/2026
Calrec (Booth C6907) and Grass Valley (Booth C2408) announced a long-term broadc...
19/04/2026
Oracle is bringing a multi-partner demonstration of Media over QUIC (MoQ)-based live streaming to NAB Show 2026, showcasing how independent systems from multipl...
19/04/2026
Encompass Digital Media announced an expanded partnership with Oracle Cloud Infr...
19/04/2026
The NAB Show is in full swing, and the SVG and SVG Europe editorial teams are chasing down the hottest stories from all over the Las Vegas Convention Center. He...
19/04/2026
Blackmagic Design has announced the ATEM 4 M/E Constellation IP and ATEM 4 M/E Constellation IP Plus, two SMPTE 2110-native live production switchers. The ATEM ...
19/04/2026
Now available in VST3, AU and AAX formats
Waves have recently released an update that extends their vocal-alignment plug-in's capabilities to all DAWs -...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Amagi, the agentic industry cloud platform for unified broadcast, streaming, and monetization, today announced that AccuWeather , the most trusted source of wea...
19/04/2026
Calrec (Booth:C6907) and Grass Valley (Booth: C2408) are today announcing a long-term broadcast audio technology partnership at NAB Show 2026. The companies are...
19/04/2026
Ikegami announces a further expansion to its range of on-camera viewfinders. Scheduled for introduction on Ikegamis Central Hall booth C3819 at the April 19th -...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/04/2026
Wuppertal April 19, 2026
Riedel's SimplyLive Solution Powers Centralized V...
19/04/2026
Wuppertal April 19, 2026
Bridge Digital and Riedel Build Campus Wide ST 2110 N...
19/04/2026
Wuppertal April 19, 2026
Riedel Showcases Next Advances in IP-Based Production at NAB 2026MediorNet HorizoN ST 2110 MultiViewer App, SmartPanel Commentary Con...
19/04/2026
Harmonic's Cloud-Native VOS Media Software Lowers Costs by Unifying Media Playout to Delivery on a Single Platform SAN JOSE, Calif. - April 19, 2026 - Harmo...
18/04/2026
MultiDyne Video & Fiber Optic Systems has begun shipping the C16-AM-12G audio mo...
18/04/2026
FOR-A America is set to detail AI functionality for its software-defined IMPULSE...
18/04/2026
Cobalt Digital and SineSix Media have announced a partnership to integrate the v...
18/04/2026
The ATSC, the broadcast standards association, is highlighting the status of the ATSC 3.0 internet protocol-based broadcast standard at the 2026 NAB Show. The e...